Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option
Ιωάννα Λαζανά(King's College Hospital), Reuben Benjamin(King's College London), Steve Schey(King's College London), T. Christmas(King's College Hospital), Paul Bassett, Victoria Potter(King's College Hospital NHS Foundation Trust), Kirsty Cuthill, Lajos Flóró(King's College Hospital), M. Kazmi(St Thomas' Hospital), Matthew Streetly(King's College - North Carolina), Antonio Pagliuca, Sapna Shah(King's College London), Kate Bramham(King's College - North Carolina)
Cited by 25
Related Papers
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2016|538
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|386